

1 **Effect of the monostearate/monopalmitate ratio on oral**
2 **release of active agents from monoacylglycerols**
3 **organogels**

4 *F. R. Lupi¹, V. Mancina¹, N. Baldino¹, O.I. Parisi², L. Scrivano², D. Gabriele¹*

5

6 ¹ Department of Information, Modelling, Electronics and System Engineering,
7 (D.I.M.E.S.) University of Calabria, Via P. Bucci, Cubo 39C, I-87036 Rende (CS),
8 Italy

9 francesca.lupi@unical.it; mancina.valentina@gmail.com; noemi.baldino@unical.it;
10 domenico.gabriele@unical.it; ortensiailaria.parisi@unical.it; luca.scrivano@unical.it

11

12 ² Department of Pharmacy, Health and Nutritional Sciences, University of Calabria,
13 Edificio Polifunzionale, I-87036 Rende (CS), Italy

14

15 **Corresponding author**

16 Dr. Domenico Gabriele

17 Department of Information, Modelling, Electronics and System Engineering
18 (D.I.M.E.S.)

19 Via P. Bucci – Cubo 39C

20 I-87036 Arcavacata di Rende (CS), Italy

21 Email: domenico.gabriele@unical.it

22 Tel. +39 0984 496687; Fax +39 0984 494009

DOI: 10.1039/c8fo00594j

© <2018>. This manuscript version is made available under the CC-BY-NC-ND 4.0 license
<https://creativecommons.org/licenses/by-nc-nd/4.0/>

23 **ABSTRACT**

24 Delivery of active agents from organogels is becoming an important topic owing to the
25 possibility of releasing, in a controlled way, lipophilic agents. Controlled release from
26 foods is a topic with increasing relevance owing to the growing industrial interest
27 towards functional or medical foods, i.e. foods containing nutraceutical agents or drugs.
28 Anyway, release properties are related to the rheological properties of organogels, and,
29 therefore, a deep knowledge of their microstructure and physical characteristics is
30 necessary to design carriers with expected release properties. In this work, two low
31 molecular weight gelators (i.e. glycerol monopalmitate, GMP, and glycerol
32 monostearate, GMS) have been investigated using rheology, microscopy and infrared
33 spectroscopy, IR, aiming at understanding the effects of different gelator ratios on
34 organogel properties. It was observed that GMP, within the range of investigated
35 compositions, seems to be more effective in yielding consistent organogels and this
36 effect was related to differences in microstructure with respect to GMS. Their ability to
37 control oral release of active agents was investigated, *in vitro*, using a chemotherapeutic
38 drug for adenocarcinoma of the gastrointestinal tract, 5 fluorouracil (5-FU). A physical
39 model based on carrier erosion was used to describe the release data, evidencing a good
40 agreement with experimental values. Among the tested samples it seems that the use of
41 90% of GMS (over total organogelator content) yields promising results allowing a
42 good partition of the released drug between the gastric and intestinal tracts with the
43 largest value (although lower than 40% of loaded amount) of the total released drug.

44 **Keywords:** *organogel; oleogel; MAGs; glycerol monostearate; glycerol monopalmitate;*
45 *5 FU; controlled release*

46 1. INTRODUCTION

47 In the last few years, the interest in organogels (or oleogels), used alone or mixed to
48 hydrogels for producing bigels as matrices for controlling delivery of active agents, has
49 been increasing as confirmed by the number of recent papers or reviews focusing on this
50 topic¹⁻⁶. Oleogels are soft solids based on an organic solvent (an oil) structured by a
51 network of organogelators that can be classified mainly in two groups, according to
52 their molecular weight⁷: polymeric (PO) or Low Molecular Weight (LMW) gelators.

53 In food applications, the former are not so common and currently only ethyl cellulose is
54 widely investigated in the literature⁸; on the other hand, food grade LMW gelators, such
55 as alkanes and waxes, fatty acids and fatty alcohols, monoglycerides, phytosterols and
56 others^{8, 9}, are more diffused; they can act through different gelation mechanisms like
57 fatty acids crystallization, self-assembled fibrillary network, reverse spherical micelles⁹.

58 In the recent past, the most investigated uses of these materials were addressed to the
59 food industry⁹, with the main purpose of substituting saturated fats in shortenings or
60 margarines with healthier components able to impart the same rheological
61 characteristics to the food¹⁰ or as stabilising systems in oil-based food suspensions¹¹.

62 Nevertheless, drug delivery (through both oral intake and transdermal topical use) is
63 becoming a new and very promising alternative for these materials that, owing to their
64 characteristics, could be suitable for the production of food matrices able to control the
65 release and the gastrointestinal absorption of active agents (both nutraceuticals or
66 pharmaceuticals). Many of them, in fact, are lipophilic, therefore they could be
67 dispersed more easily in an oil based system that could improve also the release and the
68 oral bioavailability¹². It is worth noticing that there is a significant attention of

69 pharmaceutical and food industry to the design of food matrices having specific and
70 desired properties. These systems should be able to improve the release and the
71 bioavailability of lipophilic agents that could be either nutraceuticals, to be used in
72 functional foods, or pharmaceuticals, to be used in the so-called "medical foods", i.e.
73 foods containing a drug to treat a specific diseases ¹². Starting from these
74 considerations, a further investigation on delivery properties of edible oleogels and their
75 relation to macroscopic characteristics, such as rheological properties, can be important
76 to improve the current knowledge on this topic with the aim of designing food matrices
77 for functional or medical uses.

78 From a microstructural point of view, organogels can be described as a network of
79 organogelator molecules that aggregate into crystals and in their clusters. This network
80 is able to entrap the organic solvent within avoiding liquid phase separation (syneresis).
81 In addition, the organogel network is also able to entrap other particles or, simply, to
82 stabilise them preventing their motion, such as aqueous phase droplets (forming W/O
83 emulsions such as margarines substitutes), active agents (medical or functional foods)
84 or other gels or solid particles (gelled emulsions or bigels). To explain better this
85 classification, a schematic representation of organogels and their potential applications
86 is shown in Fig. 1

87 Among the different edible gelators investigated in the literature, monoacylglycerols
88 (MAGs, also called monoglycerides of fatty acids) have a big market and they are
89 among the most studied, even in the recent literature ¹³⁻¹⁶. Commercial MAGs are often
90 produced by transesterification of fatty acids with glycerol, or synthesized via
91 glycerolysis of triacylglycerol with alkaline catalysts under a nitrogen gas atmosphere
92 ¹⁷. This category of additives is commonly appreciated for their aptitude in stabilising

93 emulsions or food systems in general ¹⁸, or as gelling agents of oil phases eventually
94 used, in turn, to produce biphasic gels. For example, McSweeney et al. ¹⁹ studied infant
95 formula emulsions evidencing the effect of two emulsifiers, lecithin and
96 monoglycerides, on their stability, whereas Davies et al. ²⁰, investigated a protocol to
97 obtain oil-in-water emulsions produced with glycerol monooleate (GMO) as the
98 emulsifier. Recently, Rafanan and Rousseau ²¹ used GMO and polyglycerol
99 polyricinoleate for emulsifying and promoting crystallisation of fat phase in water-in-oil
100 emulsions, and, moreover, pure glycerol monostearate (GMS) or mixtures with fatty
101 alcohol were also used to stabilise the oil phase (organogels) of bigels (organogel-in-
102 hydrogel) ^{22, 23}. As far as pure organogels investigation is concerned, different papers
103 give detailed descriptions of the role of MAGs in edible oil structuration ²⁴⁻³².

104 A number of papers available in the literature discuss the properties of materials
105 produced with pure GMS used alone or mixed with other additives as an oil phase
106 gelator ^{27, 33-35}, whereas pure GMP is never used for producing gels but always in a
107 commercial mixture with GMS.

108 In fact, most of the commercial MAGs are a mixture of GMP and glycerol monostearate
109 (GMS) in different proportions and according to the ratio of GMP over GMS, the
110 characteristics of the resulting organogel can be different. Lopez-Martinez et al. ³¹
111 investigated organogels based on both commercial monoglycerides (made of GMS
112 37.7% and GMP 54%) and analytical grade monoglycerides (GMS 93.51%) in
113 safflower oil and they evidenced that the commercial mixture yields organogels with
114 higher values of storage modulus and higher solid fat content and with improved ability
115 to retain oil with respect to the pure GMS. These results were also confirmed when

116 MAGs mixtures, with similar composition, were used in canola oil with and without
117 ethylcellulose³⁶.

118 Apart from these works, a lack of knowledge is currently evident in the literature about
119 the effect of the GMS/GMP ratio on the physical properties and microstructure of
120 organogels and on their potential uses.

121 In this work, organogels based on an edible oil (olive oil) and structured with MAGs
122 having a different GMP/GMS ratio were investigated for producing matrices for oral
123 delivery of active agents. From this point of view, the rheological properties of an
124 organogel matrix can optimise the control of the agent to be delivered in the right period
125 of time (not too fast, and not even too delayed)³⁷⁻³⁹. The specific interest of the research
126 is mainly focused on the release of lipophilic agents modelled both with *in vivo* or *in*
127 *vitro* methods, paying particular attention to the release kinetics.

128 The investigated organogels were produced with different mixtures of GMP and GMS
129 with the aim of tuning the rheological properties of matrices for controlling the drug
130 release. 5 fluorouracil (5-FU), a well-known chemotherapeutic active agent for
131 adenocarcinoma of the colon, rectum, breast, stomach, pancreas⁴⁰, was chosen as active
132 molecule to be released, exploring the potential use of these matrix in medical foods.
133 Nevertheless, it is worth noticing that this agent was used to represent a class of agents
134 that have to be released in a controlled way in the gastro-intestinal tract. Investigation
135 and data analysis were performed independently of the chemotherapeutic nature of the
136 agent (for instance no investigation on drug activity was developed) with the aim of
137 studying the relation between release properties and formulation (the GMP/GMS ratio).

138 The investigation was carried out with a rheological characterisation based on both
139 small amplitude oscillation and steady in-flow tests. Rheological properties with
140 temperature were also compared with microstructural investigation based on IR spectra
141 and a rheo-optical analysis for the visual inspection of crystals forming the network. A
142 number of samples was loaded with 5-FU and its delivery with time from matrices was
143 investigated with *in-vitro* tests, giving also an interpretation of the release mechanism
144 with a model able to take into account the matrix erosion with time during the
145 gastrointestinal transit.

146

147 **2. MATERIALS AND METHODS**

148 The rheological investigation of organogels was based on samples produced by keeping
149 constant the total amount of organogelators (MAGs), but varying the ratio of GMP over
150 GMS.

151 **2.1 Materials**

152 Organogels were produced with a virgin olive oil (De Santis, Italy) as the solvent. GMS
153 ($C_{21}H_{42}O_4$, ACEF, Italy) was used pure (OS100 in table 1), or combined with Myverol
154 18 04 K, a commercial mixture of GMP ($C_{19}H_{38}O_4$) and GMS (equal mass fraction)
155 supplied by Kerry Group (Ireland). Adopted ratios are reported in table 1 where
156 investigated samples and their ID are shown.

157 In vitro bioavailability tests were carried out with several solvents and chemicals,
158 among which: 5-Fluorouracil 99% (HPLC grade), α -amylase and pancreatin from pig
159 pancreas, dialysis tubing cellulose membrane (cut-off: 12-14 kDa), methanol, sodium

160 bicarbonate (NaHCO_3) (-40 to +140 mesh), pepsin from pig gastric mucosa, and sodium
161 azide (all supplied by Sigma-Aldrich, USA), hydrochloric acid (37%, Panreac, Italy),
162 phosphoric acid (85%), sodium dihydrogen phosphate ($\text{NaH}_2\text{PO}_4\cdot\text{H}_2\text{O}$) and sodium
163 hydrogen phosphate (Na_2HPO_4) all supplied by Carlo Erba (Italy) and HPLC-grade
164 water (VWR Chemical, Italy).

165 **2.2 Methods**

166 Organogels (100 mg for each sample) were prepared with an equal total amount of
167 gelators, but varying the ratio of GMS and GMP according to the composition reported
168 in table 1. The amount of pure GMS added to Myverol was progressively increased in
169 each sample, obtaining the mass fractions reported in table 1. Only samples produced
170 with 70, 80 and 90% of GMS of total MAGs were also loaded with the active agent 5-
171 FU to investigate its release.

172 2.2.1 Organogels preparation

173 As already described in previous papers^{27,28}, organogels were prepared by warming the
174 oil up to 70°C in a continuously stirred beaker (stirrer RW 20, IKA, Germany)
175 thermostated with a water bath (plate heater Jolly 2, Falc Instruments, Italy). When the
176 oil reached the desired temperature, the gelators were added allowing their complete
177 melting. After further 5 minutes of rest time (continuing to stir the liquid), samples were
178 directly loaded into the rheometer geometry, where optical and rheological tests were
179 carried out.

180 Samples for IR spectroscopy investigation were prepared following the procedure
181 already described. Then, melted organogels were stored at room temperature until the

182 gelation was completed; samples were stored at room temperature for one week and
183 afterwards 0.02 g was loaded into the measurement chamber to be investigated.

184 As far as the organogels loaded with 5-FU are concerned, after the gelators addition,
185 also 5-FU was added to the melted oil phase, since the temperatures reached were not so
186 high as to damage it ⁴¹. Afterwards, melted organogels were poured inside capsule-
187 shaped moulds in order to obtain pills of approximately 0.7 grams each; afterwards,
188 samples were allowed to cool down to room temperature. A control sample, labelled as
189 'FO', was produced adding 5-FU to pure liquid oil, in order to compare the release
190 ability of the organogels to that of the corresponding unstructured sample. The ratio 5-
191 FU/oil was kept constant and equal to 0.016.

192 2.2.2 Rheological and rheo-optical characterisation

193 Rheological characterisation of samples was carried out with both small amplitude
194 oscillation tests (SAOTs) and steady shear tests. Dynamic temperature ramp tests (time
195 cure) at 1 Hz and Step Rate Temperature Ramp Tests (SRTRTs) at 1 and 10 s⁻¹ were
196 performed with a strain controlled rheometer (ARES RFS, TA instruments, USA)
197 equipped with a parallel plate geometry of $\phi=50\text{mm}$, (gap=1±0.1 mm) with a Peltier
198 system acting under the lower plate for the thermal control of the sample. Temperature
199 was decreased from 70°C down to 10°C with a cooling rate of 1°C/min. Preliminary
200 strain sweep tests at 1 Hz were carried out to determine the linear viscoelastic regime ²⁹
201 over the whole investigated range of temperature.

202 Rheo-optical analysis was performed with a stress controlled rheometer HAAKE
203 MARS III (Thermo Scientific, Germany) equipped with a RheoScope module (camera
204 Foculus FO232TB monochrome, magnification of the lens 20X, Thermo Scientific,

205 Germany) for which a parallel plate geometry (polished plate, $\phi=60\text{mm}$, gap= 1 ± 0.1
206 mm) and a Peltier system were adopted. Micrographs were taken manually at the
207 temperature values corresponding to noticeable changes detected in time cure tests.

208 Both SAOTs and SRTRTs were used to evaluate the onset of crystallisation temperature
209 T_{co} corresponding to the temperature at which a sudden increase of the complex
210 modulus or viscosity according to the test, and, contemporary, a strong decrease in
211 phase angle was encountered. The mathematical methods adopted for evaluating these
212 values are the same as already described by Lupi et al.^{29, 30}. Moreover, gelation
213 temperature T_g has been assumed as the value corresponding to the crossover between
214 dynamic moduli, i.e. a phase angle of 45° ²⁹.

215 In some cases, experimental data were compared among them with a statistical analysis
216 based on a *t-student* test (Microsoft Excel 2016, Microsoft Office, USA). Differences
217 among values were considered significant at *p-value* < 0.01 (interval of confidence of
218 99%). All data fitting was performed through Table Curve 2D Software (Jandel
219 Scientific, USA).

220 2.2.3 IR characterisation

221 IR absorption spectra of organogels and pure organogelators mixtures were collected at
222 room temperature (about 20°C) using a Nicolet iS-10 FT-IR spectrometer (Thermo
223 Scientific, USA) equipped with a Smart iTX ATR sampling accessory. Spectra were
224 detected within the range of wavenumber between 400 and 4000 cm^{-1} (data spacing
225 0.482 cm^{-1} , 64 scans for each test). Organogels were prepared as already discussed.
226 Curves analysis, including the calculation of peak intensity (i.e. the areas under the

227 peaks), if necessary, were carried out with the software Spectragryph 1.2.8 (Dr.
228 Friedrich Menges Software-Entwicklung, Germany).

229 2.2.4 *In vitro* drug bioavailability and delivery tests

230 *In vitro* bioavailability tests were performed in simulated gastro-intestinal environment,
231 employing the previously published protocol ³⁸. Samples for the experiments were
232 prepared as follows: 5-FU-loaded organogels were obtained by putting the same
233 amounts of drug in the organogelators/olive oil mixtures at 70°C (Table 1). Afterwards,
234 they were poured in the moulds in order to obtain the final formulations. As control and
235 as blank, a solution of 5-FU in olive oil and organogels without 5-FU were also
236 prepared, respectively. The test is based on two enzymatic phases: pepsin digestion,
237 which occurs in 2 h, and pancreatic digestion, which occurs in the following 4 h.

238 2.2.4.1 *Pepsin digestion*

239 The capsules containing 5-FU and prepared with different GMP/GMS ratios, blank
240 capsule and 5-FU olive oil solution were put in different dialysis bags, each filled with 1
241 ml of 0.85 N HCl solution, 3 ml of 0.04% sodium azide (NaN₃) solution and 44 mg of
242 porcine pepsin. The membranes were carefully sealed at each end and immersed in 20
243 ml 0.85 N HCl solution. Systems were incubated in a shaking water bath at 37 ± 0.5°C
244 for 2 h, in order to simulate gastric digestion.

245 2.2.4.2 *Pancreatic digestion*

246 Following the gastric phase, the membranes were recovered, opened and 1.3 ml of 0.8
247 M NaHCO₃ solution, 11 mg of amylase and 11 mg of porcine Pancreatin were added to
248 them. The dialysis bags were then sealed again and placed in 20 ml of phosphate buffer

249 saline (PBS) solution at pH 7.0. The samples were incubated again at $37 \pm 0.5^\circ\text{C}$ for
250 further 4 h.

251 2.2.4.3 HPLC analysis

252 At the end of the time points, volumes of the releasing media were analysed by HPLC.
253 The instrument is made up of a Jasco pump PU-2080 Plus and a Jasco UV detector
254 2075 Plus. A $250 \times 4,60$ mm CN column, packed with $5 \mu\text{m}$ particles (Phenomenex,
255 Torrance, CA, US) was employed, the mobile was made of water/methanol/phosphoric
256 acid (97.95/2/0.05) and the flow rate was 0.5 ml/min.

257 2.2.3 Total weight loss tests

258 Organogel capsules (unloaded samples OS70, OS80 and OS90) were placed in 5 ml
259 sintered glass filters ($\text{Ø}10$ mm; porosity, G3, i.e. 16-40 μm nominal maximum pore
260 size), weighed and immersed in 0.85 N HCl for 2 h and then in PBS solution at pH 7.0
261 for 4 h, in order to evaluate material weight loss in gastro-intestinal simulating fluids.
262 Every 30 min, the excess of water was removed first by percolation and then by
263 centrifugation for 5 min at 2000 rpm. Finally, the filters were weighed and organogel
264 masses were calculated by subtraction of the filter tare. Percentages of mass loss were
265 obtained using the following equation:

$$266 \quad \text{Mass loss (\%)} = \frac{[(W_{tx} - W_f) - (W_{t0} - W_f)]}{(W_{t0} - W_f)} \times 100 \quad (1)$$

267 In which W_{tx} , W_f and W_{t0} represent the weight of filter with the organogel at different
268 time points, the weight of the empty filter and the weight of the filter with organogel at
269 0 h.

270

271 **3. RESULTS AND DISCUSSION**272 **3.1 Organogel-based capsules**

273 The oral route of drugs administration is the most commonly used one due to several
274 advantages, such as its simplicity and convenience, which result in an improved patient
275 compliance. On the other hand, this way of administration present some limits including
276 a variable bioavailability affected by several factors such as first-pass metabolism, acid
277 stability and enzymatic degradation, the presence of food, gastric emptying time and
278 intestinal motility, metabolism and transport.

279 5-Fluorouracil is one of the most important anticancer drugs. This antineoplastic agent
280 is a nucleoside metabolic inhibitor used in the treatment of colon, rectum, breast,
281 stomach and pancreas cancer but its efficacy could be limited by its pharmacokinetics.
282 Recently, several clinical studies highlighted that chemotherapeutic regimens involving
283 oral 5-FU drugs are not inferior compared to the continuous 5-FU infusion
284 chemotherapy⁴².

285 Based on these considerations, in the present research study, organogels for 5-FU
286 delivery were prepared with the aim to develop organogel-based capsules for the oral
287 administration of this therapeutic agent. This kind of dosage form, indeed, is
288 characterized by different advantages including ease of handling and transport and high
289 patient compliance. Organogels allow drugs to be delivered via a simple administration
290 route, such as the oral one, enhancing the bioavailability and promoting the drug
291 protection against degradation processes. Moreover, organogels-based capsules are

292 characterized by a high simplicity of production, flexible storage conditions and the
293 possibility of using natural biodegradable starting materials; therefore, they can find a
294 potential application for the oral administration of 5-FU improving its bioavailability.

295

296 **3.2 Rheological characterisation of organogels**

297 Organogels are known for their thermoreversibility, for their soft-solid consistency
298 below T_{co} , and because their behaviour is a function of the quality and the quantity of
299 organogelator added to the solvent, as well as of its chemical characteristics. Organogels
300 studied in this work follow the described behaviour, and, as an example, Fig. 2 shows
301 the time cure test in terms of G^* (Fig. 2a) and phase angle δ (Fig. 2b) of unloaded
302 samples (OS50-OS100). Time cure tests reveal a liquid-like behaviour of systems
303 (evidenced by phase angle values close to 90° starting from high temperatures down to
304 T_{co} (T_{co} values of samples are listed in table 1; they were computed by both SAOTs
305 and steady tests). Viscosity curves (which are shown in the supplementary material in
306 figs. SM1 and SM2) retrace the qualitative behaviour of complex moduli, and the onset
307 of crystallisation found in time cure tests corresponds to the same temperature values
308 found for each samples in step rate tests at 1 s^{-1} (Table 1, $p > 0.01$). If the shear rate is
309 increased to 10 s^{-1} , the qualitative trend of viscosity as temperature function is the same
310 as observed at 1 s^{-1} , but the estimated T_{co} becomes significantly different with respect
311 to data at 1 s^{-1} (according to the *t-student* test) if the ratio $X_{GMS} = \text{GMS/MAGs}$ is higher
312 than 0.7. Figure 3 shows the value of ΔT_{co} evaluated as

$$313 \quad \Delta T_{co} = T_{co}_{1\text{s}^{-1}} - T_{co}_{10\text{s}^{-1}} \quad (2)$$

314 as a function of X_{GMS} . It is interesting to notice that the difference between T_{co}
315 evaluated at the two values of shear rate according to the GMS content, and, in
316 particular, it increases with the amount of GMS added to the system, up to an apparent
317 plateau, evidenced at X_{GMS} higher than 0.7. These experimental evidences point out the
318 higher “efficiency” of GMP in stabilising the organogel network with respect to GMS.
319 In fact, when a fraction of GMP of at least 0.3 is present within the organogelator
320 mixture, the crystallisation of samples is a unique function of the organogelator amount
321 and it does not depend on the kinematics conditions adopted for carrying out the tests.

322 Some interesting considerations about sample rheology can be evaluated at a
323 temperature value far below T_{co} , so that the crystalline network is completely formed,
324 avoiding data analysis in the transition region⁴³. Rheological parameters, G^* , δ and η at
325 both the investigated shear rate, were examined at $T = 20^\circ\text{C}$, and the results are shown
326 in Figure 4 in terms of viscosity (Fig. 4a) and G^* and δ (Fig. 4b) as a function of X_{GMS} .
327 Viscosity decreases monotonously increasing GMS and an apparent plateau can be
328 noticed at $X_{GMS}=0.8$ for the lowest imposed shear rate; increasing further GMS content,
329 viscosity values can be considered constant within the range described by the error bars.
330 At 10 s^{-1} the downward trend reaches the constant value of viscosity at $X_{GMS}=0.7$. This
331 difference is caused, probably, by the more intense shear action at 10 s^{-1} that hinders the
332 network formation and yields an apparent plateau at a very low viscosity (close to 0.5
333 Pa·s).

334 When complex modulus (examined in linear condition, where, by definition, the sample
335 is not damaged by the investigation technique) is considered, it can be seen that it
336 decreases in a monotonous way if GMS increases and no plateau can be noticed in this
337 case, supporting the hypothesis that the previously discussed viscosity plateau can be

338 attributed to shear action on the forming network. On the other hand, a different trend is
339 exhibited by the phase angle that seems to reach a maximum (equivalent to a minimum
340 degree of structuration) at $X_{\text{GMS}} \approx 0.8$ suggesting a variation in organogel microstructure.
341 Apparently, more structured materials (i.e. with lower phase angle values) are obtained
342 when pure GMS or Myverol are used, whereas different ratios yields to less structured
343 systems.

344 In order to reassume the rheological results so far described, it can be concluded that the
345 variation of the ratio of GMS over GMP within a fixed mass fraction of monoglycerides
346 of fatty acids added to the oil has a strong influence on the final consistency and
347 thermorheological properties of organogels. In particular, at a temperature value lower
348 than the onset of crystallisation (i.e. 20°C), GMP seems to be more “efficient” than
349 GMS in imparting stiffness to the gel and, in fact, this result is highlighted by the trend
350 of G^* with the mass fraction of GMS that decreases monotonously, whereas the phase
351 angle shows a maximum value at $X_{\text{GMS}} \approx 0.8$, as already discussed. As far as the “in-
352 flow” results are concerned, they partly retrace what was already deduced from small
353 amplitude oscillation tests, showing a viscosity decrease in cold conditions when GMS
354 increases. Nevertheless, it has to be said that viscosity curves show a slope change
355 increasing the amount of GMS that varies with the adopted shear rate. Even the
356 thermorheological parameters T_{CO} and T_g are affected by the ratio between the two
357 monoglycerides: they both decrease when GMS increase, and T_{CO} calculated from
358 SAOTs is comparable just to the T_{CO} derived from SRTRT at 1s^{-1} i.e. the lowest
359 adopted shear rate, whereas increasing shear rate, these temperature are no longer
360 comparable. Thus, it is evident that the extra-ethyl group of GMS is able to weaken the
361 organogel matrix, owing to an increased steric encumbrance. Different ratios of

362 monoglycerides could be used in order to tune the final properties of the material
363 according to their final use, in terms of consistency and thermal stability. For instance,
364 in the particular case described in this paper, the matrix used for the active agent
365 delivery should be consistent enough to avoid an immediate release of the molecule, but
366 not too strong to delay its erosion preventing the release of the right amount of agent.

367 **3.3 IR spectroscopy**

368 IR spectroscopy is a valid tool to understand the intermolecular interactions that
369 promote gel formation. According to the literature^{44, 45}, LMW organogelators are able
370 to self-assemble creating the crystalline network thanks to the establishment of weak
371 interactions such as H-bonds or van der Waals. In particular, it has been found that
372 MAGs network formation in olive oil is principally promoted by H-bonds occurring
373 between the –OH free groups in the glycerol molecule and the C=O groups of fatty
374 acids⁴⁶ and a minor contribution is given by the van der Waals interactions standing
375 between fatty acids tails²⁸. In an IR spectrum of MAGs organogels, the most interesting
376 wavenumber region is in the range 2500-4000 cm⁻¹ where both kinds of interactions can
377 be identified. Figure 5a shows IR spectra of samples at 20°C measured after 1 week of
378 storage at room temperature. As also pointed out by the circle in the figure, the broad
379 peaks corresponding to the wavenumber region between 3000 and 3500 cm⁻¹ are
380 representative of stretching modes of glycerol –OH groups⁴⁶.

381 Generally speaking, the shift of these prominent peaks towards lower energy regions
382 with respect to a condition of unstructured (and, therefore, unlinked) samples, suggests
383 the H-bond formation⁴⁷, which, obviously hinders the chain mobility. On the contrary,

384 the increase in peaks broadness can be attributed to the increase in the number of
 385 vibrating -OH groups potentially creating bonds⁴⁸.

386 As shown by the enlargement of the region of interest shown in fig. 5a, peaks shape and
 387 broadness changes considerably, passing from small inflections of the spectrum in
 388 sample OS100 to a well-developed twin peak in sample OS50. Therefore, it can be
 389 speculated that the increase in GMS fraction results in the reduction of peak area of the
 390 corresponding organogel, and a lower propensity to give H-bonds as a consequence
 391 (this could explain the rheological behaviour described). As a confirmation of this
 392 experimental evidence, the peak intensities, i.e. the areas under the OH groups' peak
 393 (A_{OH}) calculated in a wavenumber range between 3649 and 3049 cm^{-1} were evaluated,
 394 applying an individual baseline for each curve. Fig. 5b shows the relation between G' of
 395 each organogel with the corresponding area A_{OH} , highlighting a monotonous trend of the
 396 rheological parameter with the number of vibrating OH groups, in turn responsible for
 397 H-bonds formation. In previous works, a fractal nature of the organogels rheology as a
 398 function of the organogelator content was already discussed^{28,43} and it was shown that
 399 the storage modulus G' can be related to the solid fat fraction, Φ , by the so-called
 400 "modified fractal model"⁴⁹:

$$401 \quad G' = \lambda \left(1 - e^{-k\Phi^b} \right)^{\frac{1}{3-D}} \quad (3)$$

402 In eq. 3, λ is a constant according to the strength of the interactions between crystal
 403 aggregates; D is the fractal dimension of the system (for MAGs organogel a mean value
 404 of 2.74 was obtained in previous works, see Lupi et al.²⁸); k and b are constants linked
 405 to the number of clusters within the fat⁴⁹.

406 It is worth noticing that, in organogel, the solid fraction corresponds to the
 407 organogelator molecules that, interacting with each other, build the crystalline network.
 408 As a consequence, it seems reasonable to assume that the solid fraction, Φ , is a function
 409 of the interactions (in the present case only H bonding) among organogelator molecules
 410 that, in turn, can be described by the area of OH groups peak in the IR spectra. Starting
 411 from these considerations a further modification of the fractal model (Eq. 3) could be
 412 proposed, introducing a dependence on the peak area A_{OH} :

$$413 \quad G' = \lambda \left(1 - e^{-k' A_{OH}^{b'}} \right)^{\frac{1}{3-D}} \quad (4)$$

414 Experimental data were fitted with eq. 4, assuming $D=2.74$, and a very good agreement
 415 of experimental data and fitting curve was observed (see Fig. 5b), obtaining $\lambda=1330$ Pa
 416 ± 80 Pa, $k'=0.022 \pm 0.005$ cm/% and $b' = 0.719 \pm 0.004$.

417 If the pure organogelators spectra are considered, GMS usually shows a broad peak
 418 with a small shoulder²⁷, whereas Myverol is characterised by a well developed twin
 419 peak²⁸. In the twin peak appearing in all the spectra, the higher wavenumber peak
 420 corresponding to about 3309 cm^{-1} is the peak of the 3-OH group⁴⁶ whereas the other
 421 one (at about 3237 cm^{-1}) is the peak given by the vibration mode of 2-OH. This last
 422 group, according to Chen and Terentjev⁴⁶, dominates and eventually replaces the other
 423 bonds completely in building the network. In fact, the authors suggest that with aging,
 424 3-OH hydrogen bonding is not stable and tends to reduce, playing only a secondary role
 425 in MAGs organogel structuration. This transition, during aging, corresponds to the
 426 transition from a sub- α crystal phase to a more ordered β crystal phase⁴⁶.

427 About this, the ratio between the transmittance values of peaks 2-OH over 3-OH ($t_{2-OH/3-OH}$ in Fig. SM3 shown in the supplementary material) decreases with the increase of
428 $t_{2-OH/3-OH}$ in Fig. SM3 shown in the supplementary material) decreases with the increase of
429 GMS fraction, even if the range is very narrow. Therefore, it is probable that the
430 additional ethyl group, which distinguishes GMS from GMP, hinders group 2-OH,
431 preventing it from forming an H-bond. This should further explain the higher
432 consistency of the resulting organogel produced with the major content of GMP.

433

434 **3.4 Rheo-optical analysis: photomicrographs**

435 A rheo-optical analysis was carried out for both time cure and in-flow tests to evaluate
436 the evolution of crystals in terms of shape and dimension during measurement. Fig. 6
437 shows the crystalline microstructure of samples OS50, OS70 and OS100 at 20°C
438 obtained with time cure tests and with SRTRTs at both the adopted shear rate values.
439 Going from sample OS50 (containing the minimum amount of GMS with respect to the
440 other samples studied in this work) to OS100 (prepared with the maximum amount of
441 GMS), the crystalline shape changes considerably: crystals are fibres of different
442 dimensions for sample OS50, and in particular they appear slightly bigger in the case of
443 SAOTs tests. In the latter case, the dimension of fibres do not seem to be affected
444 dramatically by the increase in the shear rate value. Increasing the amount of GMS,
445 crystals arrange into big spherical aggregates of plate-like crystals (as already observed
446 by Hwang et al.⁵⁰ for sunflower wax crystals formed in an edible oil organogel)
447 whereas a spherulite nature, evidenced by the Maltese cross⁵¹, appears when GMS is
448 the only organogelator. These crystalline arrangements could explain the rheological
449 differences given by the use of GMS and GMP mixtures of gelator.

450

451 **3.5 Release of 5-FU: a pharmaceutical application**

452 Considering the results discussed about the rheological properties of organogels, it is
453 clear that the most consistent samples were obtained with the highest amount of GMP
454 added to the oil in the mixture of organogelators. These results led to some speculation
455 for the selection of samples for 5-FU delivery by oral administration. Too consistent
456 samples could ensnare the active agent reducing its availability, whereas samples with a
457 low consistency could give a too fast a release of the active agent. Therefore, only 3
458 samples, with a GMS content varying from 70 to 90%, were chosen for the
459 pharmaceutical experimentation. *In vitro* tests were divided into two subsequent steps
460 simulating the transition of the material into the gastro-intestinal tract. The first step
461 lasted 2 hours, the second, 4 hours, for a total duration of the experiment of 6 hours.
462 Figure 7 shows the release of 5-FU, in terms of fraction released in each tract (the
463 “gastric” and the “intestinal” tract), with respect to initial drug mass. In the gastric tract,
464 a little amount (about 14.5% for the less structured sample) of the active agent is
465 released by the organogels, whereas the pure unstructured oil releases 75.8% of the
466 compound. In the subsequent simulated tract, the maximum amount of 5-FU (about
467 21.1%) is released by the most unstructured sample (FOS90) and, obviously, by pure
468 oil. It is worth noticing that the proper release of the active agent should be balanced
469 within the gastro-intestinal tract allowing the molecule to be properly delivered in the
470 section of the lumen where it should exert the therapeutic activity⁵². Of course, pure oil
471 does not control this release, concentrating the delivery of the active agent almost totally
472 in the first two hours following the oral administration.

473 The release process, of active agents from a matrix, can occur according to different
474 mechanisms based either on diffusion of the drug through the matrix or on dissolution
475 of the carrier (or on the combination of both of them)^{53,54}. In the first case, the dosage
476 forms remain intact and the active agents diffuses within the matrix to the surface, then
477 it is transferred to the surrounding medium (through the interface) and, finally, it is
478 transported away from the surface⁵⁴. In the second case, the carrier erodes releasing the
479 agent and changing the dimension (and the external surface) with time: erosion can be
480 heterogeneous (degradation occurs within a thin external layer) or homogenous
481 (degradation occurs throughout the polymer matrix)⁵⁴. Erosion can occur in
482 combination with diffusion and the final release rate depends on both of them or on the
483 limiting mechanism.

484 Different models were proposed in the literature to describe the release rate and the
485 amount of released agents. One of the first models was proposed by Higuchi to describe
486 the diffusion mechanism; assuming that internal diffusion can be described by Fick's
487 law and using some simplifying hypothesis (see the work by Raza⁵³ for further details)
488 he obtained:

$$489 \quad Q = A\sqrt{D(2C_0 - C_s)C_s t} = k_H t^{\frac{1}{2}} \quad (5)$$

490 where Q is the released drug in time t per unit area A , D is the diffusion coefficient, C_0
491 and C_s are the initial and the equilibrium concentration of agent, respectively, and k_H is
492 the Higuchi constant. Among the further different models proposed in the literature, the
493 empirical Korsmeyer-Peppas equation⁵⁵ has been widely used, with good results, to
494 describe drug delivery from polymeric systems⁵³ and also from organogels^{38, 56}. This

495 model relates the cumulative fraction of released drug, $F(t)$, to process time, t , with a
 496 power law:

$$497 \quad F(t) = k_l t^n \quad (6)$$

498 where k_l is the release rate constant (i.e. a specific release rate) and n is the release
 499 exponent. According to the literature,^{38, 57} if the matrix into which the molecule is
 500 entrapped is spherical, if n is lower than 0.43 the diffusion release can be considered as
 501 Fickian, for $0.43 \leq n \leq 0.85$ an “anomalous” non-Fickian mechanism is present, and,
 502 finally for $n \geq 0.85$, the transport is of the type case II, involving matrix dissolution;
 503 when $n=1$ the release follows a zero order kinetic corresponding to a constant release
 504 rate⁵³. Therefore, this model seems able to describe the effects of different release
 505 mechanisms.

506 When erosion is the controlling mechanism a mathematical model was developed by
 507 Hopfenberg to describe the released rate from a matrix assuming that surface area
 508 remains constant during degradation process^{53, 54}:

$$509 \quad \frac{M_d(t)}{M_{d\infty}} = 1 - \left[1 - \frac{k_0 t}{C_0 r} \right]^n \quad (7)$$

510 where $M_d(t)$ is the drug mass within the carrier at each time t , $M_{d\infty}$ the total amount of
 511 active agents that can be released (in infinite time), C_0 is the initial agent concentration
 512 within the carrier, k_0 is the erosion constant, r is the initial characteristic dimension of
 513 the carrier (radius for cylinder and sphere, length for a slab) and n an exponent
 514 dependent on the geometry ($n=1$ for slab, 2 for cylinder, 3 for sphere). Further different

515 models proposed to describe the release rate from different systems (based on erosion
516 and /or diffusion) are described more in detail by Pothakamury et al.⁵⁴ , Raza et al.⁵³.

517 Even if delivery from organogel is becoming an interesting topic, so far specific release
518 models for these materials do not exist, according to the literature it seems that matrix
519 erosion or erosion-diffusion phenomena can be the most important mechanisms and the
520 Korsmeyer-Peppas equation (Eq. 6) has been used with positive results^{38, 56}.

521 Nevertheless, a different approach could be proposed based on the investigation and
522 modelling of erosion phenomena; starting from these considerations, in order to better
523 investigate the mechanism of release from the organogelled matrix, the erosion profile
524 of carriers was investigated monitoring the total volume loss from samples within 6 h.
525 In figure 8, data are expressed as dimensionless residual volume (i.e. volume at time t ,
526 $V(t)$, divided by initial volume, V_0) of the selected organogels (OS70, OS80 and OS90),
527 at different time points. It is worth noticing that, assuming an approximately spherical
528 geometry, it holds:

$$529 \quad \left(\frac{V(t)}{V_0} \right) = \left(\frac{M(t)}{M_0} \right) = \left(\frac{R(t)}{R_0} \right)^3 \quad (8)$$

530 where M is the volume of organogel sample and R is the radius of the sphere, subscript
531 "0" refers to initial condition (i.e. at time $t=0$).

532 The volume profile as a function of time can be divided into two phases: phase I, up to
533 approximately 120 min, corresponding to the gastric step, in which material erosion is
534 fast, and phase II, from 120 on, in which the process slows down. At the end of the
535 tests, all the samples lost around 40% of their initial volume. It is worth noticing that,
536 owing to experimental difficulties, the error, for each point, is very large and this makes

537 the differences among tested samples insignificant. Anyway, if only the mean values are
538 considered, it can be seen that organogels with higher amounts of GMP, more
539 consistent, showed a reduced percentage of mass loss, with respect to those with higher
540 amounts of GMS. In particular, the highest difference can be observed by comparison of
541 OS90 and OS80 to OS70.

542 According to the literature⁵⁸ different models, mainly based on experimental data, were
543 proposed to describe the matrix erosion, among them the so-called "root type model"
544 seems able to fit a wide range of experimental results:

$$545 \quad \frac{V(t)}{V_0} = \left(\frac{R(t)}{R_0} \right)^3 = 1 - (k_0 t)^a \quad (9)$$

546 where k_0 is the erosion rate constant and a is a fitting parameter. This model was used to
547 fit experimental values, evidencing a very good agreement (see Fig. 7) and obtained
548 parameters are reported in table 2.

549 Release kinetic can be modelled describing the mass transport between the carrier and
550 the surrounding fluid. If it is assumed that the main mechanism involved in drug release
551 is matrix erosion and, therefore, neglecting potential concentration profiles within the
552 carrier, it can be written:

$$553 \quad \frac{dM_d(t)}{dt} = N_d A \quad (10)$$

554 where $M_d(t)$ is the drug mass within the carrier at each time t , A is the carrier external
555 surface, and N_d is the drug flux from the carrier towards the fluid; this can be described

556 in terms of a transport coefficient k_c and a driving force that is given by the
 557 concentration difference in the liquid phase ⁵⁹:

$$558 \quad N_d = -k_c (c_s - c(t)) \quad (11)$$

559 where $c(t)$ is the drug mass concentration in the surrounding fluid at time t and c_s the
 560 drug equilibrium solubility at the experimental temperature ⁵³.

561 Assuming that the drug concentration in the liquid, $c(t)$, is much lower than the
 562 solubility limit (i.e. working under "sink" conditions, ⁵³) it can be neglected with respect
 563 to c_s and eq. 11 becomes

$$564 \quad \frac{dM_d(t)}{dt} = -k_c A c_s = -k_2 A \quad (12)$$

565 Where the solubility limit, being constant, has been included in k_2 that represents, in the
 566 present case, a specific release rate with a meaning similar to that of the Korsmeyer-
 567 Peppas constant k_1 .

568 It is worth noticing that, when matrix erosion occurs, the external surface area is not
 569 constant with time, therefore its change with time should be properly described to take
 570 into account the effects on drug release. If eq. 9 is used to describe the volume evolution
 571 and a spherical geometry is assumed, the evolution of external surface can be described
 572 as:

$$573 \quad \frac{A(t)}{A_0} = \left(\frac{R(t)}{R_0} \right)^2 = \left(1 - (k_0 t)^a \right)^{\frac{2}{3}} \quad (13)$$

574 where A_0 is the external surface at time 0. By replacing eq. 13 in eq. 12, it holds:

575
$$\frac{dM_d(t)}{dt} = -k_2 A(t) = -k_2 (4\pi R_0^2) (1 - (k_0 t)^a)^{\frac{2}{3}} \quad (14)$$

576 This equation can be solved using the initial condition $t=0, M_d(t)=M_{d0}$ obtaining:

577
$$1 - \frac{M_d(t)}{M_{d0}} = F(t) = \frac{k_2}{M_{d0}} (4\pi R_0^2) \int_0^t (1 - (k_0 t)^a)^{\frac{2}{3}} dt \quad (15)$$

578 The constant k_2 can be estimated following the procedure commonly adopted in
 579 chemical kinetic analysis and based on the integral method of data analysis⁶⁰: eq. 15 is
 580 adopted to describe experimental data at time $t= 2$ h and $t= 6$ h, obtaining two values for
 581 the missing kinetic constant. If the suggested model is suitable to describe experimental
 582 data, the obtained values of kinetic constants are very similar each to the other (within
 583 the experimental error) and their mean value can be assumed as k_2 ⁶⁰.

584 Obtained parameters for samples FOS70, FOS80 and FOS90 are shown in Table 3, in
 585 terms of mean value and standard deviation, it can be seen that, except for sample
 586 FOS80, deviation is very low (lower than 10%), within the expected experimental error,
 587 suggesting that the model is able to describe the data and therefore confirming the
 588 validity of the assumptions used. Table 3 reports the values of k_1 and n for the same
 589 samples: for all samples a value of n ranging between 0.43 and 0.85 was found,
 590 evidencing a potential anomalous diffusion mechanism.

591 Figure 9 shows the delivery data in terms of $F(t)$ with time for samples FOS70, FOS80
 592 and FOS90; in addition the fitting curves of the Korsmeyer–Peppas model (eq. 6) and
 593 erosion model (eq. 15) are reported.

594 It is worth noticing that deviation between erosion model (eq. 15) and experimental data
595 is approximately 5% for samples FOS70 and FOS90 whereas it is 14% for FOS80; this
596 suggests that the model, although very simple, is able to describe experimental data
597 strengthening the hypothesis of erosion controlled release. Moreover, it has a greater
598 physical meaning than empirical fittings because it is based on a (simplified) physical
599 description of observed phenomena and could be improved further removing some
600 simplifying hypotheses.

601 The Korsmeyer–Peppas model, being a fitting equation with two adjustable parameters,
602 describes almost perfectly the experimental data; nevertheless, it seems less related to
603 the physical phenomena involved in the process.

604 Further tests, where a larger number of data are collected, seem necessary to
605 discriminate better between different mechanisms evidencing the potential need to
606 introduce a diffusion term in the mass balance equation.

607

608 **4. CONCLUSIONS**

609 This paper describes the thermo-rheological properties and the drug release
610 characteristics of oleogels based on virgin olive oil and a mixture of glycerol
611 monopalmitate (GMP) and glycerol monostearate (GMS). These low molecular weight
612 organogelators are adopted in different areas, nevertheless they are commonly used in
613 commercial mixtures, and therefore, few data are available on the effects of their ratio
614 on macroscopic properties of obtained organogels.

615 A deep rheological investigation, based on dynamic and steady tests, evidenced that
616 GMP is more efficient than GMS in organogel production, making more consistent gels
617 with lower crystallization and gelation temperatures. These macroscopic differences can
618 be attributed to different microstructures, according to the results of rheo-optical and IR
619 characterisation. In fact, it was observed that, increasing GMS content, the crystalline
620 shape changes from a fiber-like structure to spherical clusters. Moreover, when the two
621 peaks associated with H bonding in infrared spectra are considered, the ratio between
622 peak heights and the peak intensities are a function of the GMS/GMP ratio and the
623 observed trend suggests the presence of fewer interactions with increasing amount of
624 GMS.

625 These results can be extremely useful in tuning organogel properties as a function of the
626 specific use; in the present work, they were used to develop a potential carrier for
627 controlled drug delivery, using 5 fluorouracil (5-FU) as the molecule to be released.
628 Experimental *in vitro* tests, evidenced, as expected, that organogels can yield a
629 controlled and progressive release of the drug, with respect to the unstructured oil.
630 Among tested samples the organogel containing 90% of GMS (over the total MAGs
631 content) seems the most promising because it yields a total release of approximately
632 40% of total loaded drug, with the largest fraction released in the intestinal tract.
633 Nevertheless, the formulation should be investigated further to enhance the total
634 released amount (currently quite low).

635 Drug release data has been described by a very simple physical model based on carrier
636 erosion that has proven itself to fit experimental value very well (the largest deviation
637 was 14%); this seems to confirm (according also to other literature works) that erosion
638 is the most important mechanism involved in drug release from organogels.

639

640 **5. ACKNOWLEDGMENTS**

641 The authors are grateful to Dr Roberta Bianco for carrying out in-flow tests.

642

643 **REFERENCES**

644

- 645 1. C. L. Esposito, P. Kirilov and V. G. Roullin, Organogels, promising drug
646 delivery systems: an update of state-of-the-art and recent applications, *Journal of*
647 *Controlled Release*, 2018, **271**, 1-20.
- 648 2. Q. Zhang, Y. M. Song, S. W. Page and S. Garg, Evaluation of Transdermal Drug
649 Permeation as Modulated by Lipoderm and Pluronic Lecithin Organogel, *Journal of*
650 *Pharmaceutical Sciences*, 2018, **107**, 587-594.
- 651 3. Z. L. Li, B. Zhang, S. H. Jia, M. F. Ma and J. C. Hao, Novel supramolecular
652 organogel based on beta-cyclodextrin as a green drug carrier for enhancing anticancer
653 effects, *Journal of Molecular Liquids*, 2018, **250**, 19-25.
- 654 4. D. E. Liu, Q. X. Chen, Y. B. Long, J. B. Ma and H. Gao, A thermo-responsive
655 polyurethane organogel for norfloxacin delivery, *Polymer Chemistry*, 2018, **9**, 228-235.
- 656 5. S. P. Kodela, P. M. Pandey, S. K. Nayak, K. Uvanesh, A. Anis and K. Pal,
657 Novel agar-stearyl alcohol oleogel-based bigels as structured delivery vehicles,
658 *International Journal of Polymeric Materials and Polymeric Biomaterials*, 2017, **66**,
659 669-678.
- 660 6. A. Shakeel, F. R. Lupi, D. Gabriele, N. Baldino and B. De Cindio, Bigels: A
661 unique class of materials for drug delivery applications, *Soft Materials*, 2018, 1-17.
- 662 7. A. R. Patel, in *Edible Oil Structuring: Concepts, Methods and Applications*, The
663 Royal Society of Chemistry, 2018, pp. 1-22.
- 664 8. E. D. Co and A. G. Marangoni, Organogels: An Alternative Edible Oil-
665 Structuring Method, *Journal of the American Oil Chemists Society*, 2012, **89**, 749-780.

- 666 9. A. J. Martins, A. A. Vicente, R. L. Cunha and M. A. Cerqueira, Edible oleogels:
667 an opportunity for fat replacement in foods, *Food & Function*, 2018, **9**, 758-773.
- 668 10. N. Siraj, M. A. Shabbir, T. Ahmad, A. Sajjad, M. R. Khan, M. I. Khan and M. S.
669 Butt, Organogelators as a Saturated Fat Replacer for Structuring Edible Oils,
670 *International Journal of Food Properties*, 2015, **18**, 1973-1989.
- 671 11. F. R. Lupi, D. Gabriele, N. Baldino, L. Seta, B. de Cindio and C. De Rose,
672 Stabilization of meat suspensions by organogelation: A rheological approach, *European*
673 *Journal of Lipid Science and Technology*, 2012, **114**, 1381-1389.
- 674 12. D. J. McClements and H. Xiao, Excipient foods: designing food matrices that
675 improve the oral bioavailability of pharmaceuticals and nutraceuticals, *Food &*
676 *Function*, 2014, **5**, 1320-1333.
- 677 13. M. D. Bin Sintang, S. Danthine, A. Brown, D. Van de Walle, A. R. Patel, I.
678 Tavernier, T. Rimaux and K. Dewettinck, Phytosterols-induced viscoelasticity of
679 oleogels prepared by using monoglycerides, *Food Research International*, 2017, **100**,
680 832-840.
- 681 14. D. Kouzounis, A. Lazaridou and E. Katsanidis, Partial replacement of animal fat
682 by oleogels structured with monoglycerides and phytosterols in frankfurter sausages,
683 *Meat Science*, 2017, **130**, 38-46.
- 684 15. C. Palla, A. Giacomozzi, D. B. Genovese and M. E. Carrín, Multi-objective
685 optimization of high oleic sunflower oil and monoglycerides oleogels: Searching for
686 rheological and textural properties similar to margarine, *Food Structure*, 2017, **12**, 1-14.
- 687 16. M. D. B. Sintang, T. Rimaux, D. V. d. Walle, K. Dewettinck and A. R. Patel, Oil
688 structuring properties of monoglycerides and phytosterols mixtures, *European Journal*
689 *of Lipid Science and Technology*, 2017, **119**, 1500517.

- 690 17. H. Nouredini and V. Medikonduru, Glycerolysis of fats and methyl esters,
691 *Journal of the American Oil Chemists' Society*, 1997, **74**, 419-425.
- 692 18. J. Blazek, E. P. Gilbert and L. Copeland, Effects of monoglycerides on pasting
693 properties of wheat starch after repeated heating and cooling, *Journal of Cereal Science*,
694 2011, **54**, 151-159.
- 695 19. S. L. McSweeney, R. Healy and D. M. Mulvihill, Effect of lecithin and
696 monoglycerides on the heat stability of a model infant formula emulsion, *Food*
697 *Hydrocolloids*, 2008, **22**, 888-898.
- 698 20. E. Davies, E. Dickinson and R. Bee, Shear stability of sodium caseinate
699 emulsions containing monoglyceride and triglyceride crystals, *Food Hydrocolloids*,
700 2000, **14**, 145-153.
- 701 21. R. Rafanan and D. Rousseau, Dispersed droplets as active fillers in fat-crystal
702 network-stabilized water-in-oil emulsions, *Food Research International*, 2017, **99**, 355-
703 362.
- 704 22. F. R. Lupi, M. P. De Santo, F. Ciuchi, N. Baldino and D. Gabriele, A rheological
705 modelling and microscopic analysis of bigels, *Rheologica Acta*, 2017, **56**, 753-763.
- 706 23. F. R. Lupi, A. Shakeel, V. Greco, C. Oliviero Rossi, N. Baldino and D. Gabriele,
707 A rheological and microstructural characterisation of bigels for cosmetic and
708 pharmaceutical uses, *Materials Science and Engineering: C*, 2016, **69**, 358-365.
- 709 24. A. Alfutimie, N. Al-Janabi, R. Curtis and G. J. T. Tiddy, The Effect of
710 monoglycerides on the crystallisation of triglyceride, *Colloids and Surfaces A:
711 Physicochemical and Engineering Aspects*, 2016, **494**, 170-179.
- 712 25. A. Alfutimie, R. Curtis and G. J. T. Tiddy, Gel phase (L β) formation by mixed
713 saturated and unsaturated monoglycerides, *Colloids and Surfaces A: Physicochemical
714 and Engineering Aspects*, 2014, **456**, 286-295.

- 715 26. N. K. Ojijo, I. Neeman, S. Eger and E. Shimoni, Effects of monoglyceride
716 content, cooling rate and shear on the rheological properties of olive oil/monoglyceride
717 gel networks, *Journal of the Science of Food and Agriculture*, 2004, **84**, 1585-1593.
- 718 27. F. R. Lupi, A. Shakeel, V. Greco, N. Baldino, V. Calabrò and D. Gabriele,
719 Organogelation of extra virgin olive oil with fatty alcohols, glyceryl stearate and their
720 mixture, *LWT - Food Science and Technology*, 2017, **77**, 422-429.
- 721 28. F. R. Lupi, V. Greco, N. Baldino, B. de Cindio, P. Fischer and D. Gabriele, The
722 effects of intermolecular interactions on the physical properties of organogels in edible
723 oils, *Journal of Colloid and Interface Science*, 2016, **483**, 154-164.
- 724 29. F. R. Lupi, D. Gabriele, D. Facciolo, N. Baldino, L. Seta and B. de Cindio,
725 Effect of organogelator and fat source on rheological properties of olive oil-based
726 organogels, *Food Research International*, 2012, **46**, 177-184.
- 727 30. F. R. Lupi, D. Gabriele and B. de Cindio, Effect of Shear Rate on Crystallisation
728 Phenomena in Olive Oil-Based Organogels, *Food and Bioprocess Technology*, 2012, **5**,
729 2880-2888.
- 730 31. A. Lopez-Martinez, J. A. Morales-Rueda, E. Dibildox-Alvarado, M. A. Charo-
731 Alonso, A. G. Marangoni and J. F. Toro-Vazquez, Comparing the crystallization and
732 rheological behavior of organogels developed by pure and commercial monoglycerides
733 in vegetable oil, *Food Research International*, 2014, **64**, 946-957.
- 734 32. S. Da Pieve, S. Calligaris, E. Co, M. C. Nicoli and A. G. Marangoni, Shear
735 Nanostructuring of Monoglyceride Organogels, *Food Biophysics*, 2010, **5**, 211-217.
- 736 33. T. Pénczes, G. Blazsó, Z. Aigner, G. Falkay and I. Erős, Topical absorption of
737 piroxicam from organogels—in vitro and in vivo correlations, *International Journal of*
738 *Pharmaceutics*, 2005, **298**, 47-54.

- 739 34. T. Péntzes, I. Csóka and I. Erős, Rheological analysis of the structural properties
740 effecting the percutaneous absorption and stability in pharmaceutical organogels,
741 *Rheologica Acta*, 2004, **43**, 457-463.
- 742 35. R. Sanchez, J. M. Franco, M. A. Delgado, C. Valencia and C. Gallegos,
743 Rheology of oleogels based on sorbitan and glyceryl monostearates and vegetable oils
744 for lubricating applications, *Grasas Y Aceites*, 2011, **62**, 328-336.
- 745 36. A. Lopez-Martinez, M. A. Charo-Alonso, A. G. Marangoni and J. F. Toro-
746 Vazquez, Monoglyceride organogels developed in vegetable oil with and without
747 ethylcellulose, *Food Research International*, 2015, **72**, 37-46.
- 748 37. A. Vintiloiu and J.-C. Leroux, Organogels and their use in drug delivery — A
749 review, *Journal of Controlled Release*, 2008, **125**, 179-192.
- 750 38. F. R. Lupi, D. Gabriele, N. Baldino, P. Mijovic, O. I. Parisi and F. Puoci, Olive
751 oil/policosanol organogels for nutraceutical and drug delivery purposes, *Food &*
752 *Function*, 2013, **4**, 1512-1520.
- 753 39. S. Uzan, D. Bariş, M. Çolak, H. Aydın and H. Hoşgören, Organogels as novel
754 carriers for dermal and topical drug delivery vehicles, *Tetrahedron*, 2016, **72**, 7517-
755 7525.
- 756 40. A. Fallah Shojaei, K. Tabatabaeian, S. Shakeri and F. Karimi, A novel 5-
757 fluorouracil anticancer drug sensor based on ZnFe₂O₄ magnetic nanoparticles ionic
758 liquids carbon paste electrode, *Sensors and Actuators B: Chemical*, 2016, **230**, 607-614.
- 759 41. P. Singh, G. Tyagi, R. Mehrotra and A. K. Bakhshi, Thermal stability studies of
760 5-fluorouracil using diffuse reflectance infrared spectroscopy, *Drug Testing and*
761 *Analysis*, 2009, **1**, 240-244.

- 762 42. K. Miura, M. Kinouchi, K. Ishida, W. Fujibuchi, T. Naitoh, H. Ogawa, T. Ando,
763 N. Yazaki, K. Watanabe, S. Haneda, C. Shibata and I. Sasaki, 5-FU Metabolism in
764 Cancer and Orally-Administrable 5-FU Drugs, *Cancers*, 2010, **2**, 1717.
- 765 43. F. R. Lupi, D. Gabriele, V. Greco, N. Baldino, L. Seta and B. de Cindio, A
766 rheological characterisation of an olive oil/fatty alcohols organogel, *Food Research*
767 *International*, 2013, **51**, 510-517.
- 768 44. J. H. van Esch and B. L. Feringa, New Functional Materials Based on Self-
769 Assembling Organogels: From Serendipity towards Design, *Angewandte Chemie*
770 *International Edition*, 2000, **39**, 2263-2266.
- 771 45. S. Wu, J. Gao, T. J. Emge and M. A. Rogers, Influence of solvent on the
772 supramolecular architectures in molecular gels, *Soft Matter*, 2013, **9**, 5942-5950.
- 773 46. C. H. Chen and E. M. Terentjev, Aging and Metastability of Monoglycerides in
774 Hydrophobic Solutions, *Langmuir*, 2009, **25**, 6717-6724.
- 775 47. M. Suzuki, T. Abe and K. Hanabusa, Low-molecular-weight gelators based on
776 N-alpha-acetyl-N-epsilon-dodecyl-L-lysine and their amphiphilic gelation properties,
777 *Journal of Colloid and Interface Science*, 2010, **341**, 69-74.
- 778 48. S. Shin, J. Jang, S. H. Yoon and I. Mochida, A study on the effect of heat
779 treatment on functional groups of pitch based activated carbon fiber using FTIR,
780 *Carbon*, 1997, **35**, 1739-1743.
- 781 49. D. Tang and A. G. Marangoni, Modified fractal model and rheological
782 properties of colloidal networks, *Journal of Colloid and Interface Science*, 2008, **318**,
783 202-209.
- 784 50. H.-S. Hwang, S. Kim, K. O. Evans, C. Koga and Y. Lee, Morphology and
785 networks of sunflower wax crystals in soybean oil organogel, *Food Structure*, 2015, **5**,
786 10-20.

- 787 51. B. Crist and J. M. Schultz, Polymer spherulites: A critical review, *Progress in*
788 *Polymer Science*, 2016, **56**, 1-63.
- 789 52. R. Kumar, S. Patil, M. B. Patil, S. R. Patil and M. S. Paschapur, Design and In
790 vitro Evaluation of Oral Floating Matrix Tablets of Aceclofenac, *International Journal*
791 *of ChemTech Research*, 2009, **1**, 10.
- 792 53. S. N. Raza and N. A. Khan, Role of mathematical modelling in controlled
793 release drug delivery, *International Journal of Medical Research and Pharmaceutical*
794 *Sciences*, 2017, **4**, 84-95.
- 795 54. U. R. Pothakamury and G. V. Barbosa-Cánovas, Fundamental aspects of
796 controlled release in foods, *Trends in Food Science & Technology*, 1995, **6**, 397-406.
- 797 55. R. W. Korsmeyer, R. Gurny, E. Doelker, P. Buri and N. A. Peppas, Mechanisms
798 of solute release from porous hydrophilic polymers, *International Journal of*
799 *Pharmaceutics*, 1983, **15**, 25-35.
- 800 56. K. Iwanaga, T. Sumizawa, M. Miyazaki and M. Kakemi, Characterization of
801 organogel as a novel oral controlled release formulation for lipophilic compounds, *Int J*
802 *Pharm*, 2010, **388**, 123-128.
- 803 57. J. Siepmann and F. Siepmann, Mathematical modeling of drug delivery,
804 *International Journal of Pharmaceutics*, 2008, **364**, 328-343.
- 805 58. S. You, Z. Yang and C.-H. Wang, Toward Understanding Drug Release From
806 Biodegradable Polymer Microspheres of Different Erosion Kinetics Modes, *Journal of*
807 *Pharmaceutical Sciences*, 2016, **105**, 1934-1946.
- 808 59. R. B. Bird, W. E. Stewart and E. N. Lightfoot, *Transport Phenomena*, John
809 Wiley and sons, Inc., USA, 2nd edn., 2007.

810 60. J. M. Smith, *Chemical Engineering Kinetics*, McGraw-Hill International Edition,
811 3rd edn., 1981.

812

813

814 **TABLES CAPTIONS**

815

816 Table 1 Samples ID and composition; onset of crystallisation temperature, T_{co} , at
817 1 and 10 s^{-1} are calculated by SRTRTs; the ratio 5FU/oil is constant and equal to 0.016.

818 Table 2 Fitting parameters of eq. 6 applied to experimental data of samples OS70,
819 OS80, OS90

820 Table 3 Korsmeyer-Peppas model parameters (k_1 and n , eq. 6) and erosion model
821 parameter (k_2 , eq. 15) for samples FOS70, FOS80, FOS90.

822

823 **FIGURES CAPTIONS**

824 Figure 1 Schematic representation of organogels and their uses: organogelator
825 molecules aggregate into crystals and clusters creating the organogel. In turn, different
826 other fillers can differentiate among the possible uses of organogels

827 Figure 2 Dynamic temperature ramp tests of samples OS50 (red diamond), OS60
828 (blue square), OS70 (open circle), OS80 (green circle), OS90 (purple triangle), OS100
829 (brown cross). Complex modulus G^* (a) and phase angle δ (b).

830 Figure 3 ΔT_{co} vs $x_{GMS} = GMS/MAGs$; ΔT_{co} is calculated according to eq. (1)

831 Figure 4 Rheological parameters at $T=20^\circ\text{C}$ for different glycerol monostearate
832 fraction, X_{GMS} . (a) Viscosity, η , calculated at 1s^{-1} (solid circles) and 10s^{-1} (open
833 circles); (b) complex modulus, G^* , (solid circles) and phase angle, δ , (open circles).

834 Figure 5 Infrared spectra of organogels (a) and storage modulus, G' , at 20°C
835 versus A_{OH} , experimental data (symbols) and modified fractal model (eq. 4) (b)

836 Figure 6 Micrographs of samples OS50, OS70 and OS100 taken with the
837 rheoscope tool during temperature ramp tests in dynamic (SAOT) and steady (SRTRT)
838 conditions. Reference bar is $50\ \mu\text{m}$.

839 Figure 7 Fraction of 5-FU released in each tract (the “gastric” and the “intestinal”
840 tract) with respect to initial drug mass. Gastric phase refers to the *in vitro* step
841 simulating the gastric tract; intestinal phase refers to the *in vitro* step simulating the
842 intestinal tract.

843 Figure 8 Dimensionless volume profile with time of organogels capsules OS70
844 (circle), OS80 (diamond) and OS90 (square). For each sample, fitting lines refers to eq.
845 6. $V(t)$ is the capsule volume at the time t , V_0 is the initial capsule volume.

846 Figure 9 Delivery data in terms of $F(t)$ with time for samples FOS70 (circle),
847 FOS80 (diamond) and FOS90 (square); the fitting curves of the Korsmeyer–Peppas
848 model (eq. 7, solid line) and erosion model (eq. 13, dashed line) are shown.

849

Sample	Olive oil (%w/w)	GMP (%w/w)	GMS (%w/w)	5-FU (%w/w)	x_{GMS} (w/w)	T_{co} $1 s^{-1}$ (°C)	T_{co} $10 s^{-1}$ (°C)	T_{co} SAOTs (°C)	T_g (°C)
OS50	95	2.5	2.5	-	0.50	49.2±0.1	48.2±0.3	50.8±0.2	48.1±0.1
OS60	95	2	3	-	0.60	48.4±0.6	45.8±0.3	48.7±0.3	46.3±0.3
OS70	95	1.5	3.5	-	0.70	47.0±0.3	43.0±0.3	46.8±0.3	44.1±0.1
OS80	95	1	4	-	0.80	42.0±0.1	37.8±0.3	42.5±0.1	40.9±0.2
OS90	95	0.5	4.5	-	0.90	39.4±0.3	35.2±0.1	40.8±0.2	38.6±0.1
OS100	95	-	5	-	1.00	33.6±0.1	29.2±0.1	33.2±0.4	31.6±0.4
FOS70	93.5	1.5	3.5	1.5	0.70	-	-	-	-
FOS80	93.5	1	4	1.5	0.80	-	-	-	-
FOS90	93.5	1.5	4.5	1.5	0.90	-	-	-	-
FO	98.42	-	-	1.58	-	-	-	-	-

850

851

Table 1

Sample	k_0 (-)	a (-)
OS70	$(1.59 \pm 0.16) 10^{-5}$	0.430 ± 0.030
OS80	$(6.10 \pm 0.78) 10^{-6}$	0.364 ± 0.017
OS90	$(6.00 \pm 0.70) 10^{-6}$	0.404 ± 0.018

852

853

Table 2

854

Sample	$k_1 (s^{-n})$	$n (-)$	$k_2 (kg/s/m^2)$
FOS70	$(9.18 \pm 0.01) \cdot 10^{-5}$	0.760 ± 0.001	$(4.2 \pm 0.2) \cdot 10^{-3}$
FOS80	$(2.98 \pm 0.01) \cdot 10^{-4}$	0.680 ± 0.001	$(6 \pm 1) \cdot 10^{-3}$
FOS90	$(1.02 \pm 0.01) \cdot 10^{-4}$	0.818 ± 0.001	$(7.2 \pm 0.5) \cdot 10^{-3}$

855

856

Table 3

857




Figure 1 Schematic representation of organogels and their uses: organogelator molecules aggregate into crystals and clusters creating the organogel. In turn, different other fillers can differentiate among the possible uses of organogels

297x167mm (300 x 300 DPI)




Figure 2 Dynamic temperature ramp tests of samples OS50 (red diamond), OS60 (blue square), OS70 (open circle), OS80 (green circle), OS90 (purple triangle), OS100 (brown cross). Complex modulus G^* (a) and phase angle δ (b).

173x108mm (300 x 300 DPI)




Figure 2 Dynamic temperature ramp tests of samples OS50 (red diamond), OS60 (blue square), OS70 (open circle), OS80 (green circle), OS90 (purple triangle), OS100 (brown cross). Complex modulus G^* (a) and phase angle δ (b).

173x112mm (300 x 300 DPI)




Figure 3 ΔT_{co} vs $x_{GMS}=GMS/MAGs$; ΔT_{co} is calculated according to eq. (1)

170x107mm (300 x 300 DPI)




Figure 4 Rheological parameters at $T=20^{\circ}\text{C}$ for different glycerol monostearate fraction, X_{GMS} . (a) Viscosity, η , calculated at 1 s^{-1} (solid circles) and 10 s^{-1} (open circles); (b) complex modulus, G^* , (solid circles) and phase angle, δ , (open circles).

172x115mm (300 x 300 DPI)




Figure 4 Rheological parameters at $T=20^\circ\text{C}$ for different glycerol monostearate fraction, X_{GMS} . (a) Viscosity, η , calculated at 1 s⁻¹ (solid circles) and 10 s⁻¹ (open circles); (b) complex modulus, G^* , (solid circles) and phase angle, δ , (open circles).

166x108mm (300 x 300 DPI)




Figure 5 Infrared spectra of organogels (a) and storage modulus, G' , at 20°C versus AOH, experimental data (symbols) and modified fractal model (eq. 4) (b)

167x93mm (300 x 300 DPI)




Figure 5 Infrared spectra of organogels (a) and storage modulus, G' , at 20°C versus AOH, experimental data (symbols) and modified fractal model (eq. 4) (b)

169x104mm (300 x 300 DPI)




Figure 6 Micrographs of samples OS50, OS70 and OS100 taken with the rheoscope tool during temperature ramp tests in dynamic (SAOT) and steady (SRTRT) conditions. Reference bar is 50 μm .

167x93mm (300 x 300 DPI)




Figure 7 Fraction of 5-FU released in each tract (the "gastric" and the "intestinal" tract) with respect to initial drug mass. Gastric phase refers to the in vitro step simulating the gastric tract; intestinal phase refers to the in vitro step simulating the intestinal tract.

166x113mm (300 x 300 DPI)




Figure 8 Dimensionless volume profile with time of organogels capsules OS70 (circle), OS80 (diamond) and OS90 (square). For each sample, fitting lines refers to eq. 6. $V(t)$ is the capsule volume at the time t , V_0 is the initial capsule volume.

172x110mm (300 x 300 DPI)





Figure 9 Delivery data in terms of $F(t)$ with time for samples FOS70 (circle), FOS80 (diamond) and FOS90 (square); the fitting curves of the Korsmeyer–Peppas model (eq. 7, solid line) and erosion model (eq. 13, dashed line) are shown.

168x109mm (300 x 300 DPI)

GMP/GMS organogels are promising systems for oral delivery in functional or medical foods



123x82mm (300 x 300 DPI)

Effect of the monostearate/monopalmitate ratio on oral release of active agents from monoacylglycerols organogels

F. R. Lupi¹, V. Mancina¹, N. Baldino¹, O.I. Parisi², L. Scrivano², D. Gabriele¹

¹ Department of Information, Modelling, Electronics and System Engineering, (D.I.M.E.S.) University of Calabria, Via P. Bucci, Cubo 39C, I-87036 Rende (CS), Italy

francesca.lupi@unical.it; mancina.valentina@gmail.com; noemi.baldino@unical.it; domenico.gabriele@unical.it; ortensiailaria.parisi@unical.it; luca.scrivano@unical.it

² Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Edificio Polifunzionale, I-87036 Rende (CS), Italy

Corresponding author

Dr. Domenico Gabriele

Email: domenico.gabriele@unical.it




Figure SM1 Steady temperature ramp tests at 1 s^{-1} of samples OS50 (red diamond), OS60 (blue square), OS70 (open circle), OS80 (green circle), OS90 (purple triangle), OS100 (brown cross).




Figure SM2 Steady temperature ramp tests at 10 s^{-1} of samples OS50 (red diamond), OS60 (blue square), OS70 (open circle), OS80 (green circle), OS90 (purple triangle), OS100 (brown cross).




Figure SM3 Ratio between transmittance value of peak 2-OH over peak 3-OH (t_{2-OH}/t_{3-OH}) versus X_{GMS}